On 17 February 2025, Boan Biotech announced that the Journal of Bone Oncology published Phase III trial results for its biosimilar denosumab (Boluojia®/BA1102, formerly code-named LY01011), demonstrating comparable efficacy and safety to reference product, Amgen’s Xgeva®. Boluojia® is reported to have met all primary and secondary endpoints.
Boluojia® was approved for marketing in China in May 2024 for the treatment of giant cell tumours of bone, following the approval of Mabwell’s Maiweijian™ in April 2024, which was the first Chinese approved denosumab biosimilar.